Table 2.
Comparative efficacies at 1 year of available nucleos(t)ide analogs for the treatment of hepatitis B
| ALT normalization | Drop in HBV DNA (log copies/mL) | Undetectable HBV DNA by PCR | HBeAg loss | HBeAg seroconversion | HBsAg loss | HBsAg seroconversion | Histological response | |
|---|---|---|---|---|---|---|---|---|
| HBeAg positive | ||||||||
| Lamivudine25,26 | 41%–72% | 32% | 16%–17% | 0%–2% | 0% | 14%–32% | ||
| Adefovir27,28 | 48%–79% | −3.52 | 21% | 13%–24% | 8%–12% | 53% | ||
| Entecavir12,14,15 | 68%–89% | −6.9 | 58%–74% | 18%–22% | 15%–21% | 2% | 72% | |
| Telbivudine29–31 | 77%–87% | −6.56 | 60%–67% | 25%–30% | 22%–27% | 64.7% | ||
| Tenofovir32 | 68% | Not reported | 76% | 21% | 3.2% | 74% | ||
| HBeAg negative | ||||||||
| Adefovir33 | 72% | −5.23 | 51% | 64% | ||||
| Entecavir13,14 | 78%–94% | −5.22 | 90%–94% | 70% | ||||
| Telbivudine30,31 | 74.4%–100% | −5.5 | 85%–88% | 66.6% | ||||
| Tenofovir32 | 76% | Not reported | 93% | 0% | 0% | 72% |
Abbreviations: ALT, alanine aminotransferase; HBeAg, hepatitis B e antigen; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; PCR, polymerase chain reaction.